ANL
$8.02
Market ClosedAs of Mar 17, 8:00 PM UTC
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products.
Historical Price
Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$8.02
Potential Upside
5%
Whystock Fair Value$8.42
Price
UndervaluedFair ValueOvervalued
Fundamentals
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatm...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$295.94M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-138.98%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.69
Recent News
Wall Street Set to Open Lower Friday as Investors React to Trump's Choice of Warsh as Fed Chair
US stocks look set to open lower in Friday's trading session as investors seem calmed by President D
Investors Calmed by Trump's Choice of Warsh as Fed Chair, Look Ahead to Inflation Data
US stock futures are tracking lower in Friday's premarket session, but rebounding from earlier level
Individual investors are Adlai Nortye Ltd.'s (NASDAQ:ANL) biggest owners and were rewarded after market cap rose by US$65m last week
Key Insights Adlai Nortye's significant individual investors ownership suggests that the key decisions are influenced...